Italia markets open in 2 hours 56 minutes

Aeterna Zentaris Inc. (AEZS.TO)

Toronto - Toronto Prezzo in tempo reale. Valuta in CAD.
Aggiungi a watchlist
2,8200+0,2200 (+8,46%)
Alla chiusura: 03:57PM EDT
Schermo intero
Chiusura precedente2,6000
Aperto2,8000
Denaro2,8100 x 0
Lettera2,8700 x 0
Min-Max giorno2,7700 - 2,9700
Intervallo di 52 settimane1,9100 - 4,2300
Volume8.609
Media Volume2.213
Capitalizzazione13,694M
Beta (5 anni mensile)2,07
Rapporto PE (ttm)N/D
EPS (ttm)-4,6600
Prossima data utili07 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendo11 ago 1999
Stima target 1AN/D
  • GlobeNewswire

    Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

    – Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris will participate a

  • GlobeNewswire

    Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually. Dr. P

  • GlobeNewswire

    Aeterna Zentaris Reports Second Quarter 2023 Financial Results

    Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and o